Parkinson’s Vaccine Candidate Generated Antibody Response
In a small Phase 2 trial, an experimental vaccine triggered a consistent immune response in patients with early-stage Parkinson’s.
Updated on Sept. 29, 2026 in Alzheimer’s
Live Poll
Do you trust pharmaceutical companies to successfully develop new treatments for Parkinson's disease?
AC Immune has released week-100 safety and immunogenicity data from its Phase 2 VacSyn trial evaluating the experimental vaccine ACI-7104. All 34 participants in the study demonstrated an antibody response after receiving three immunizations.
Why it matters
This development represents a preliminary step in exploring immune-based therapies for Parkinson's disease, focusing on whether a vaccine can safely trigger an immune response against protein targets. Researchers aim to establish safety and biological activity before evaluating potential clinical benefits.
In the Phase 2 VacSyn trial, 100% of 25 patients receiving the ACI-7104 vaccine showed an antibody response after three immunizations compared to a placebo group of nine. This was an exploratory study evaluating safety and immunogenicity rather than clinical outcomes.
The players
AC Immune
A clinical-stage biopharmaceutical company focused on developing precision medicines for neurodegenerative diseases including Parkinson's and Alzheimer's.
FDA
The United States agency responsible for regulating food, tobacco, and medical products to ensure public health safety and efficacy.
The details
The ACI-7104 vaccine is designed to stimulate the immune system to target specific protein structures associated with Parkinson's disease pathology. Researchers observed that these generated antibodies penetrated the cerebrospinal fluid, where a signal for total alpha-synuclein was also detected. The trial focused on ensuring the vaccine is safe and tolerable for patients in the early stages of the disease.
Timeline
• Week-100 data from the Phase 2 trial was reported on September 29, 2026.
• Discussions regarding the Phase 2 part 2 trial design are planned for early 2027.
Health Landscape
This trial of ACI-7104 contributes to the broader, ongoing investigation into the safety and immunogenicity of vaccines for neurodegenerative conditions. It follows the established pattern of early-phase immunotherapy research by prioritizing safety and biological markers over functional outcomes.
This early-stage study is a research development and does not change current care for patients living with Parkinson's disease. Those interested in the status of experimental treatments should speak with their neurologist about ongoing research and clinical trial eligibility.
The takeaway
While this vaccine candidate successfully triggered an immune response in a small trial, the results do not yet confirm any clinical benefit for Parkinson's disease. Patients should continue working with their physicians to manage symptoms using standard, evidence-based treatments currently available.
Further reading
For context on the challenges of developing therapies for progressive neurological disorders, see our coverage of Alzheimer’s.
Source note: This article includes information reported by PharmaTimes.
Live Poll
Do you trust pharmaceutical companies to successfully develop new treatments for Parkinson's disease?
